CPO-100
Phase 1Small molecule
CPO-100 is one of 34 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
249 competitors in Patients With Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Tecentriq
RochePhase 2
Halaven
EisaiPhase 2
Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Ensacove
XXcovery Holdings, Inc.
Phase 2
Albumin-Bound Paclitaxel
Bristol-Myers SquibbPhase 2
Carboplatin AUC-5
Merck & Co.Phase 2
ZG005
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Utidelone
BBeijing Biostar Pharmaceuticals Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CPO-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CConjupro Biotherapeutics, Inc.